rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    ALDX
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      H.C. Wainwright reiterates Neutral on Aldeyra stock at $2 target
      Sep 30Investing.comALDX
      Aldeyra Therapeutics, Inc. (ALDX) Discusses FDRR and FDA Review Process for Reproxalap in Dry Eye Disease - Slideshow (NASDAQ:ALDX) 2026-09-30
      Sep 30Seeking AlphaALDX
      Aldeyra Therapeutics Stock Surges as It Files an FDA Dispute Resolution - Aldeyra Therapeutics (NASDAQ:AL

      Aldeyra Therapeutics stock surges as the company files an FDA dispute resolution for its dry eye drug reproxalap following a rejection.

      Sep 29BenzingaALDX
      Aldeyra to Appeal FDA Rejection of Reproxalap for Dry Eye Disease

      Aldeyra Therapeutics (NASDAQ:ALDX) said it plans to submit a formal dispute resolution request, or FDRR, to the FDA’s Office of New Drugs seeking review of the agency’s latest complete response letter for reproxalap, its investigational treatment for the signs and symptoms of dry eye disease. The c

      Sep 29Yahoo FinanceALDX
      Aldeyra Therapeutics Plans Formal FDA Dispute Resolution Request for Reproxalap After Third Complete Response Letter
      Sep 29Yahoo FinanceALDX
      Aldeyra to appeal FDA rejection of dry eye drug reproxalap
      Sep 29Investing.comALDX
      Aldeyra Therapeutics Announces Intent to Submit Formal Dispute Resolution Request for Reproxalap to Treat Dry Eye Disease
      Sep 29Yahoo FinanceALDX
      Aldeyra Therapeutics to Host Regulatory Update Webcast

      CONCORD, Mass., September 28, 2026--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced that the company will host a regulatory update webcast on Tuesday, September 29, 2026, at 8:00 a.m. ET. The update will focus on reproxalap, an investigational drug for the treatment of dry eye disease.

      Sep 28Yahoo FinanceALDX
      Aldeyra Therapeutics (ALDX) Receives a Hold from H.C. Wainwright

      Detailed price information for Aldeyra Therapeu (ALDX-Q) from The Globe and Mail including charting and trades.

      Sep 22The Globe and MailALDX

      This is the newest page. Registered accounts read further back.